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Objective  To reveal the signifi  cance of continuous transcutaneous carbon dioxide (CO2) level monitoring through 
reviewing cases which showed a discrepancy in CO2 levels between arterial blood gas analysis (ABGA) and 
continuous transcutaneous blood gas monitoring.
Method  Medical record review was conducted retrospectively of patients with neuromuscular diseases who had 
started home mechanical ventilation between June 2008 and May 2010. Th   e 89 patients underwent ABGA at the 1st 
hospital day, and changes to their CO2 level were continuously monitored overnight with a transcutaneous blood 
gas analysis device. The number of patients who initially appeared to show normal PaCO2 through ABGA, yet 
displayed hypercapnea through overnight continuous monitoring, was counted.
Results  36 patients (40.45%) presented inconsistent CO2 level results between ABGA and continuous overnight 
monitoring. Th   e mean CO2 level of the 36 patients using ABGA was 37.23±5.11 mmHg. However, the maximum 
and mean CO2 levels from the continuous monitoring device were 52.25±6.87 mmHg and 46.16±6.08 mmHg, 
respectively. From the total monitoring period (357.28±150.12 minutes), CO2 retention over 45 mmHg was 
detected in 198.97 minutes (55.69%).
Conclusion  Although ABGA only reflects ventilatory status at the puncturing moment, ABGA results are 
commonly used to monitor ventilatory status in most clinical settings. In order to decide the starting point of 
home mechanical ventilation in neuromuscular patients, continuous overnight monitoring should be considered 
to assess latent CO2 retention.
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INTRODUCTION
  In patients with neuromuscular disorders that are 
characterized by respiratory failure resulting from 
restrictive pulmonary diseases caused by respiratory 
muscle weakness, assessing the partial pressure of 
blood carbon dioxide is crucial to evaluate ventilatory 
condition.
1 Arterial blood gas analysis (ABGA) is 
known to indicate the partial pressures of blood oxygen 
and carbon dioxide accurately.
1,2 On the other hand, 
ABGA values are indicated only at the time point of 
measurement, and further to this, patients feel pain due 
to the invasiveness of the method, which may lead to 
hyperventilation or apnea. In such cases, results may 
not refl  ect patients’ usual ventilatory condition and it is 
also significant that sleep hypoventilation is a common 
symptom in patients with neuromuscular disorders.
3-5 
Thus normal values from ABGA do not necessarily 
indicate a normal ventilatory condition at all times. As 
the case stands, there is a need to analyze ventilatory 
conditions seriately by use of transcutaneous blood gas 
analysis.
6 In the department of rehabilitation medicine 
at Gangnam Severance hospital, serial measurements 
were made of the ventilatory conditions of patients 
with suspected respiratory failure or with underlying 
diseases, by use of ABGA and a transcutaneous blood gas 
analysis device, the SenTec Digital Monitor System with 
V-Sign
TM Sensor (Sentec AG, Therwil, Switzerland), on 
the premise that ABGA does not suffi   ciently refl  ect usual 
ventilatory conditions. Th   e aim of this study is to assess 
the importance of serial analysis of ventilatory conditions 
in decision-making about artificial ventilatory support 
in patients with neuromuscular disorders who have 
undergone ABGA and serial transcutaneous blood gas 
monitoring in their sleep before ventilator application.
MATERIALS AND METHODS
Subjects
  155 patients with neuromuscular disorders and 
respiratory failure to whom ventilators were prescribed 
and applied at Gangnam Severance Hospital Seoul, 
Korea between June 2008 and May 2010 were studied. 
From these 155 patients, however, 66 were excluded. 
In the case of 40 exclusions, breathing patterns in sleep 
were analyzed by end-tidal carbon dioxide (ETCO2) 
monitoring instead of transcutaneous monitoring of 
PCO2. For the other 26, original medical records relating 
their continuous respiratory patterns in sleep were 
lost, so accurate analysis of the data was impossible. 89 
patients who underwent both ABGA and continuous 
monitoring of Ptc(trans-cutaneous)CO2 on the same day 
and whose medical records were preserved were eligible 
for the study.
Methods
  Transcutaneous measurements of oxygen and carbon 
dioxide are based on the principle that a heating element 
of the sensor, which is attached to the ear lobe, elevates 
the temperature of the underlying tissues to 43 degrees 
Celsius. This increases capillary blood flow and the 
partial pressure of oxygen and carbon dioxide, and makes 
the skin permeable to gas diffusion. Chemical values, 
including the potential of hydrogen (pH), are electrically 
analyzed through a highly penetrable membrane, 
wherewith the partial pressures of oxygen and carbon 
dioxide are calculated.
7 Th   e zero point is set automatically 
when the sensor is connected to the device. Recording of 
data starts when the sensor is separated from the device 
for monitoring and stops when the sensor is reconnected 
to the device for calibration, thus the continuous data 
are saved as one complete fi  le. Th   e values are displayed 
in real time on the device. Th   e cumulative data are sent 
to the device, and time distribution of mean, maximum 
and minimum values are organized in tables and charts 
automatically (Fig. 1).
  On admission day, all targeted patients underwent 
both ABGA and continuous overnight monitoring 
of transcutaneous CO2 during sleep. We defined 
hypercapnia as partial pressure of arterial carbon dioxide 
(PaCO2)>45 mmHg,
8-10 with ventilators being applied 
to cases of hypercapnia. In the case of those patients 
whose PaCO2 were normal on ABGA but were considered 
to be hypercapnic on overnight transcutaneous 
blood gas monitoring, medical records were analyzed 
retrospectively. The maximum and mean values of 
PaCO2 and the duration of hypercapnia during overnight 
monitoring were also calculated. Th   e symptoms and signs 
of hypoventilation caused by pulmonary insufficiency, 
which include sleep disorder, headache, confusion 
and lethargy, nightmare and anxiety,
11 were evaluated 
in all targeted patients. We also verified the reduction Soon Kyu Lee, et al.
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in hypercapnia and improvement of hypoventilation 
symptoms after application of the ventilator.
RESULTS
Features of control and experimental groups
  Th   e total number of enrolled patients was 89, of whom 
53 showed hypercapnia as determined by analysis of 
both ABGA and overnight transcutaneous blood gas 
monitoring. Although ABGA was within normal range 
in the remaining 36 patients (40.45%), hypercapnia was 
observed on the overnight transcutaneous blood gas 
monitoring, which represented a marked discrepancy 
between the two studies.
  Th   e control group, who were hypercapic in both intra-
arterial and transcutaneous blood gas monitoring, 
consisted of 37 men and 16 women and the mean age 
was 44.87±21.56. Their underlying diseases consisted of 
Fig. 1. These figures show an ex-
ample of a patient’s data from the 
transcutaneous blood gas monitoring 
device. (A) Table and (B) graph of a 
patient’s data from continuous trans-
cutaneous blood gas monitoring. 
The table shows mean, maximal 
PCO2 values and portions of PCO2 
range, while the graph shows change 






Minimum 35.7 mmHg (22:04:12) 90-200 0 sec 0%
Maximum 52.8 mmHg (05:43:08) 85-89 0 sec 0%
Mean 44.7 mmHg 80-84 0 sec 0%
Baseline 45.0 mmHg 75-79 0 sec 0%
Max.above baseline 17.1 mmHg (05:43:18) 70-74 0 sec 0%
65-69 0 sec 0%
60-64 0 sec 0%
55-59 0 sec 0%
50-54 58,27 min 13%
45-49 3:00,28 hrs 39%
40-44 3:01,56 hrs 40%
35-39 38,08 min 8%
30-34 0 sec 0%
25-29 0 sec 0%
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neuromuscular disease (20), motor neuron disease (14), 
tetraplegia due to spinal cord injury (1), and Guillain-
Barre syndrome (1).
  The experimental group consisted of 25 men and 11 
women with a mean average age of 36.06±22.08. Their 
underlying disorders consisted of neuromuscular disease 
(20), motor neuron disease (14), tetraplegia due to spinal 
cord injury (1), and Guillain-Barre syndrome (1).
Ventilation in experimental group with normal PaCO2 
on ABGA but hypercapnia on overnight transcutaneous 
blood gas monitoring
  The ABGA results of the 36 patients who showed 
discrepancy between transcutaneous and arterial blood 
gases were investigated, with the mean PaCO2 being 
37.23±5.11 mmHg. On overnight transcutaneous blood 
gas monitoring, the maximum value and mean value of 
PaCO2 were 52.25±6.87 mmHg and 46.16±6.08 mmHg 
respectively. The overnight transcutaneous blood gas 
monitoring was performed for 357.28±150.12 minutes, 
during which carbon dioxide partial pressure of over 45 
mmHg occupied 198.97 minutes (55.69%).
Hypoventilation symptoms of the experimental group 
and improved ventilation after the application of 
mechanical ventilator support
  Surveys were conducted on the symptoms of hypoven-
tilation, including insomnia, daytime hypersomnolence, 
morning headaches, nightmare, and anxiety, for the 
89 patients who needed the application of a mecha-
nical ventilator before they underwent ABGA and trans-
cutaneous monitoring. Symptoms of hypoventilation were 
observed in 20 patients (37.7%) among the 53 who were 
hypercapnic in both transcutaneous blood gas monitoring 
and ABGA and in 14 patients (38.9%) among the 36 
whose ABGA fell within the normal range but in whom 
hypercapnia was observed on overnight transcutaneous 
blood gas monitoring.
Hypoventilation symptoms were eliminated in all 34 
patients after the application of mechanical ventilator 
support
  According to the overnight transcutaneous blood gas 
monitoring which was performed on the last hospital 
day for the experimental group, PaCO2 showed a 
maximum value of 38.48±7.41 mmHg and a mean value 
of 32.73±6.87 mmHg, indicating that, hypercapnia was 
not observed. In the control group, the maximum value 
and the mean value of PaCO2 were 58.97±9.41 mmHg 
and 49.54±8.61 mmHg respectively, before ventilator 
application. After the application of mechanical 
ventilator support, hypercapnia was resolved so that 
the maximum and mean PaCO2 decreased to 40.86±6.68 
mmHg, 34.48±6.08 mmHg respectively. 
DISCUSSION
  Aggravation of pulmonary insufficiency causes a 
decrease in the total time of spontaneous ventilation 
without respiratory muscle fatigue in daily living. 
Likewise, a delay in treatment of pulmonary insuffi   ciency 
may increase the burden of cardiovascular work, which 
can increase cardiovascular complications.
12,13 In early-
stage respiratory failure, mechanical ventilator support 
can resolve the fatigue of respiratory muscles. Th  erefore, 
early detection of respiratory failure and early application 
of mechanical ventilatory support is important.
14 In 
particular, it is crucial to determine when ventilatory 
support should be given, because the lifespan of patients 
with restrictive pulmonary diseases derived from 
neuromuscular disorder can be lengthened by ventilatory 
support.
14 In the case of such patients, hypercapnia 
occurs due to alveolar hypoventilation. The problem 
is that early-stage hypercapnia may occur without 
subjective symptoms.
14 Accordingly, regular evaluation of 
hypercapnia and the initiation of ventilatory support in 
case of need is critical.
  ABGA is known to be highly effective for measuring 
the partial pressures of oxygen and carbon dioxide and 
for evaluate ventilatory conditions.
15 However, it is an 
invasive method that causes pain and thus may lead to 
hyperventilation, and moreover, it cannot be performed 
on sleeping patients. Furthermore, the data are indicated 
only at the time point of measurement. Altogether, it is 
not a sufficient tool for accurate analysis of respiratory 
failure.
14,16-18 In particular, analysis of respiratory failure 
by ABGA is not suitable for patients with neuromuscular 
diseases accompanied by respiratory muscle weakness 
because in the daytime such patients show a low level of 
carbon dioxide due to hyperventilation, but overnight, 
their supine posture decreases lung capacity and 
weakens spontaneous respiration. Th  erefore,  continuous Soon Kyu Lee, et al.
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monitoring of ventilation during sleep is crucial.
  The aim of this study was to research the utility of 
continuous overnight transcutaneous blood gas 
monitoring, which was conducted in 36 patients whose 
hypercapnia was not observed on ABGA but was 
observed on the transcutaneous blood gas monitoring, 
from a total group of 89 patients with chronic respiratory 
failure caused by respiratory muscle weakness, such as 
hypercapnia, who needed ventilators. Th   ese 36 patients’ 
diff  ering results might have been because the tests were 
affected by postures, sleep states, moods and mental 
states.
4
  In this study, patients whose hypercapnia was observed 
only on overnight transcutaneous blood gas monitoring 
comprised 40.45% of the total subjects. The times at 
which hypercapnia was observed occupied over 3 hours 
of the total sleeping time. Th   is result suggests that 4 out of 
10 patients who undergo ABGA may miss an opportunity 
to receive timely treatment. Considering that early-
stage hypercapnia may be observed only during sleep, 
ventilation during sleep needs to be monitored and 
assessment should consider many factors that could 
influence ventilation, in order that respiratory failure 
may be detected early and treatment may be performed 
in time.
  In the study of Storre et al., it was found that the 
carbon dioxide partial pressure, measured by overnight 
transcutaneous blood gas monitoring, was significantly 
related to that of ABGA
6 and that the error between 
ABGA and a transcutaneous blood gas analyzer was 
1.0±5.0 mmHg.
2,6,19-24 This error is different from that 
of this study.
23 The reason for this might be that values 
were measured at different times. The difference was 
not signifi  cant, but it is nevertheless very suggestive that 
hypercapnia lasted (198.97 out of 357.28±150.12 minutes; 
55.69%) to the extent that a ventilator needed to be 
applied.
  It is most effective to make a serial analysis of arterial 
blood gas by puncturing the artery, but this is highly 
invasive and thus may cause complications such as 
infection and hemorrhage. This method is hardly 
used, except in cases for which vital signs should be 
monitored. Instead, ETCO2 analysis and transcutaneous 
blood gas monitoring are widely used as measuring 
instruments.
2,6,20 In the case of ETCO2 analysis, air may 
leak and the reliability may diff  er according to underlying 
diseases, leading to the wider usage of transcutaneous 
methods. Hinkelbein et al. and Bolliger et al. reported 
that transcutaneous methods were superior to the 
ETCO2 analysis in terms of reliability.
2,19,20 In this study, 
a transcutaneous blood gas analyzer was used on the 
authority of the report of Storre et al.
6,7,24,25
  Th   e limitation of this study is that carbon dioxide partial 
pressure was analyzed by a retrograde method using 
medical records, and thus respiratory rates could not 
be reflected. The respiratory rate is not displayed on 
the transcutaneous blood gas analyzer, and it was also 
not recorded during ABGA. As a result, the occurrence 
of hyperventilation or apnea could not be monitored. 
Nevertheless, this study confirmed that serial overnight 
transcutaneous blood gas monitoring could compensate 
for the shortcomings of ABGA. For the present, however, 
it was impossible to clarify the reason for which ABGA 
and overnight transcutaneous blood gas monitoring 
showed different results. Another problem is that this 
study was conducted without a control group from the 
normal population. Changes in body temperature were 
also not refl  ected, though the measuring instrument was 
sensitive to temperature. Mahutte et al. reported that 
the test became less reliable and that patients might be 
scalded if it was performed for over 4 hours,
26 but other 
researchers have reported that measuring hours did not 
aff  ect results signifi  cantly.
7,21,27
CONCLUSION
  The exclusive application of ABGA is insufficient to 
decide whether to apply mechanical ventilatory support. 
Considering that respiratory insufficiency may occur 
in recumbent patients with neuromuscular diseases, 
serial overnight transcutaneous blood gas monitoring 
is appropriate to evaluate their ventilatory conditions. 
Particularly in the case of patients whose diseases are 
more likely to cause respiratory muscle fatigue, carbon 
dioxide partial pressure should be periodically monitored 
in order that respiratory failure can be detected early. 
A further large-scale study should be conducted with 
various relevant indexes, including respiratory rates as 
well as the use of a normal control group.
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